Psyence Biomedical Ltd(PBM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PBM Psyence Biomedical Ltd

Market Closed 02-14 16:00:00 EST

1.40

+0.12

+8.98%

盘后1.40

+0.00+0.36%

19:59 EST

High1.40	Low1.25	Vol567.66K
Open1.28	D1 Closing1.28	Amplitude11.72%
Mkt Cap5.45M	Tradable Cap5.27M	Total Shares3.91M
T/O762.09K	T/O Rate15.04%	Tradable Shares3.77M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"PBM","market":"US","secType":"STK","nameCN":"Psyence Biomedical Ltd","latestPrice":1.395,"timestamp":1739566800000,"preClose":1.28,"halted":0,"volume":567660,"hourTrading":{"tag":"盘后","latestPrice":1.4,"preClose":1.395,"latestTime":"19:59 EST","volume":18301,"amount":25432.4686,"timestamp":1739581178001},"delay":0,"floatShares":3774821,"shares":3907100,"eps":-286.5411,"marketStatus":"Market Closed","change":0.115,"latestTime":"02-14 16:00:00 EST","open":1.28,"high":1.4,"low":1.25,"amount":762088.148046,"amplitude":0.117187,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-286.5411,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1739869200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.28,"preHourTrading":{"tag":"盘前","latestPrice":1.27,"preClose":1.28,"latestTime":"09:29 EST","volume":19645,"amount":26757.454569499998,"timestamp":1739543399745},"postHourTrading":{"tag":"盘后","latestPrice":1.4,"preClose":1.395,"latestTime":"19:59 EST","volume":18301,"amount":25432.4686,"timestamp":1739581178001},"volumeRatio":2.794165609593862},"requestUrl":"/m/hq/s/PBM/wiki","defaultTab":"wiki","newsList":[{"id":"2511217285","title":"CVS Health reward 'positively skewed'","url":"https://stock-news.laohu8.com/highlight/detail?id=2511217285","media":"Investing.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511217285?lang=en_us&edition=fundamental","pubTime":"2025-02-13 23:17","pubTimestamp":1739459833,"startTime":"0","endTime":"0","summary":"Investing.com --CVS Health is seeing signs of stabilization in key business areas, prompting Leerink Partners to upgrade the stock from Market Perform to Outperform and raise its price target to $75 per share in a note Thursday.“We see the reward as positively skewed on a risk-adjusted basis,” analysts at Leerink Partners wrote, citing improving trends in Aetna and Health Care Benefits .The firm noted that CVS shares had rebounded sharply from recent lows, which had been exacerbated by concerns over HCB and pharmacy benefit management  risks.However, with a strategic reboot of Medicare Advantage  and largely unchanged PBM and Health Services Segment  trajectories, CVS is said to now appear to be nearing the end of its challenges.Leerink Partners stated, “There may still be some puts and takes as utilization stays elevated, but that is also now more appropriately aligned with CVS' pricing model and membership growth targets.”Despite the upbeat outlook, Leerink Partners pointed to underp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cvs-health-reward-positively-skewed-151713002.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0056508442.USD","LU0109391861.USD","LU0985320562.USD","LU2092627202.USD","LU0316494557.USD","LU2764262908.HKD","LU0345770308.USD","LU1623119135.USD","LU0289941410.SGD","LU0109392836.USD","IE00BFSS8Q28.SGD","LU1629891620.HKD","IE00BJJMRX11.SGD","BK4534","IE00B4JS1V06.HKD","LU0557290698.USD","BK4550","IE00B5TLWC47.USD","LU0820562030.AUD","CVS","LU0256863811.USD","LU0823421333.USD","LU0234572021.USD","PBM","LU1852331112.SGD","LU2236285917.USD","LU1983260115.SGD","LU0006306889.USD","LU0942090050.USD","LU1989764664.SGD","LU0320765059.SGD","LU2213496289.HKD","LU0127658192.USD","LU2023250330.USD","IE00BYQQ9H92.USD","LU2417539215.USD","IE00BSNM7G36.USD","LU0868494617.USD","LU0417517546.SGD","LU0353189763.USD","LU2092937148.SGD","LU1670628061.USD","BK4139","MA","LU1059921491.USD","LU1803068979.SGD","LU0107464264.USD","IE00BQXX3D17.EUR","LU1691799644.USD","LU1363072403.SGD"],"gpt_icon":0},{"id":"2510371545","title":"CVS's stock soars after a big profit beat, continued improvement in PBM business","url":"https://stock-news.laohu8.com/highlight/detail?id=2510371545","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510371545?lang=en_us&edition=fundamental","pubTime":"2025-02-12 21:07","pubTimestamp":1739365620,"startTime":"0","endTime":"0","summary":"Health-services revenue, which includes the PBM drug 'middleman' business, fell again amid price improvements, but topped expectations. Shares of CVS Health Corp. soared in early trading Wednesday, after the drugstore chain and healthcare-services company beat quarterly profit expectations by a wide margin as the under-fire pharmacy-benefit-manager business continued to show improvement.Revenue in the company's health-services division, which includes the CVS Caremark PBM business, saw the pace of the decline in revenue slow for the fourth-straight quarter, as pharmacy drug mix and growth in specialty pharmacy helped offset pharmacy client price improvements and the previously announced loss of a large client.Also read: CVS's stock seeing worst month in decades as drug seller gets criticism from both parties.The stock  shot up 11.3% toward a three-month high in premarket trading, enough to top the S&P 500 index's SPX gainers ahead of the open.Looking ahead, the company expects 2025 adj","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKVL7J92.USD","BK4139","IE00BZ1G4Q59.USD","LU0070302665.USD","LU1059921491.USD","PBM","LU0072461881.USD","CVS","BK4581","LU0208291251.USD","LU0162691827.USD","LU1699723380.USD","BK4585","BK4196","BK4504","BK4588","LU1571399168.USD","BK4550","LU0320765489.SGD","LU0061475181.USD","LU0211331839.USD","IE00BSNM7G36.USD","LU0006061336.USD"],"gpt_icon":0},{"id":"2508753432","title":"CENTENE CORPORATION REPORTS 2024 RESULTS","url":"https://stock-news.laohu8.com/highlight/detail?id=2508753432","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508753432?lang=en_us&edition=fundamental","pubTime":"2025-02-04 19:00","pubTimestamp":1738666800,"startTime":"0","endTime":"0","summary":"-- 2024 Full Year Diluted EPS of $6.31; Adjusted Diluted EPS of $7.17 --. 2024 adjusted diluted EPS of $7.17, up 7% from $6.68 in 2023.Membership increases of 12% in Marketplace and 50% in Medicare PDP, compared to the fourth quarter of 2023.Executed on capital deployment with $3.0 billion of share repurchases in 2024.Increased 2025 premium and service revenues guidance by $4.0 billion driven by Medicaid revenue and better than expected membership performance during the annual enrollment period in Medicare Advantage and PDP.ST. LOUIS, Feb. 4, 2025 /PRNewswire/ --Centene Corporation   announced today its financial results for the fourth quarter and year ended December31, 2024. In summary, the 2024 fourth quarter and full year results were as follows:. In October, the Centers for Medicare & Medicaid Services  issued 2025 Medicare Advantage Star Ratings on the Medicare Plan Finder. Based on the data as well as our successful appeal of the initial scoring of our TTY , Centene Corporation h","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/centene-corporation-reports-2024-results-110000254.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/centene-corporation-reports-2024-results-110000254.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2362540622.SGD","LU1201861165.SGD","BK4215","BK4585","BK4208","LU0130103400.USD","LU1291159041.SGD","LU0477156953.USD","LU0130102774.USD","LU1989771016.USD","LU1699723380.USD","PBM","BK4094","CSR","LU0130517989.USD","CMS","LU2362541513.USD","LU0648000940.SGD","LU2362541273.HKD","LU2637428348.USD","BK4154","IE0034235188.USD","LU1894683348.USD","BK4588","LU0130518102.USD","CHS","LU2346227817.USD","LU1201861249.SGD","BK4139","LU0477156797.USD","CNC","LU0980610538.SGD","LU1894683264.USD","PDP","LU0648001328.SGD"],"gpt_icon":0},{"id":"2508436540","title":"2 Top Dividend Stocks to Buy If You Have $1,000 to Invest","url":"https://stock-news.laohu8.com/highlight/detail?id=2508436540","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508436540?lang=en_us&edition=fundamental","pubTime":"2025-02-04 16:40","pubTimestamp":1738658400,"startTime":"0","endTime":"0","summary":"These dividend stocks have something to offer many different types of investors.UnitedHealthcare is the world's largest healthcare company in terms of revenue.Costco is a profit powerhouse with a reliable business model.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/02/04/2-top-dividend-stocks-to-buy-if-you-have-1000-to-i/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["US6M.BOND","LU0234570918.USD","SG9999001176.USD","US30Y.BOND","BK4532","LU1496350502.SGD","US3Y.BOND","LU1934455863.HKD","LU0203347892.USD","LU0109391861.USD","LU1791710582.SGD","LU1323610961.USD","LU2023251221.USD","LU1551013425.SGD","PBM","LU0158827781.USD","LU0265550359.USD","LU1267930730.SGD","LU0198837287.USD","LU2210150020.SGD","UNH","US10Y.BOND","LU0496365809.HKD","BK4533","LU2362541273.HKD","LU2491049909.HKD","COST","LU0122379950.USD","LU1670628061.USD","LU1057294990.SGD","IE00B5TLWC47.USD","LU2360106947.USD","US12M.BOND","IE00B1XK9C88.USD","LU1069347547.HKD","LU0266013472.USD","LU2244417387.USD","LU0353189763.USD","LU1267930573.SGD","LU0965508806.USD","LU1066051811.HKD","IE00BWXC8680.SGD","LU0256863811.USD","SGXZ81514606.USD","LU1720051108.HKD","US7Y.BOND","US2Y.BOND","SG9999014906.USD","LU1035773651.USD","US5Y.BOND"],"gpt_icon":1},{"id":"2508201913","title":"Is UnitedHealth Group (UNH) One of the Best Big Name Stocks to Invest in Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2508201913","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508201913?lang=en_us&edition=fundamental","pubTime":"2025-02-01 06:30","pubTimestamp":1738362611,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 12 Best Big Name Stocks to Invest in Now.In this article, we are going to take a look at where UnitedHealth Group Incorporated  stands against other best big name stocks to invest in now.Big name stocks refer to well-known companies that are widely recognized and have a significant presence in the stock market. These companies are often industry leaders and are included in major stock indices such as the S&P 500, Dow Jones Industrial Average, or Nasdaq Composite. These companies are characterized by their large market capitalizations, stable financial performance, and strong brand recognition.To compile our list of the 12 best big name stocks to invest in now, we used Finviz and Yahoo stock screeners to identify well-known, large-cap companies, that have a significant presence in the United States stock market. We then used Insider Monkey’s Hedge Fund database to rank 12 stocks according to the largest number of hedge fund holders, as","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/unitedhealth-group-unh-one-best-223011062.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0238689110.USD","LU2552382132.HKD","PBM","LU2361044865.SGD","LU1720051108.HKD","BK4581","IE00B19Z3B42.SGD","LU0114720955.EUR","LU0787776722.HKD","LU1854103824.USD","LU0187121727.USD","IE00B19Z8W00.USD","LU0823416689.USD","BK4534","LU0965509101.SGD","LU1074936037.SGD","LU1778281490.HKD","UNH","IE00BSNM7G36.USD","LU1551013342.USD","LU0029864427.USD","SG9999001176.USD","IE00B894F039.SGD","LU1023059063.AUD","LU2089283258.USD","LU0107464264.USD","IE00B19Z3581.USD","LU1323610961.USD","LU2360032135.SGD","LU2028103732.USD","LU2361044949.HKD","LU0882574055.USD","LU2362540622.SGD","IE00B19Z9505.USD","IE00BJJMRY28.SGD","IE0004445015.USD","LU2111349929.HKD","LU1914381329.SGD","LU2112291526.USD","LU2491049909.HKD","LU0795875086.SGD","IE00BN29S564.USD","COMP","LU0417517546.SGD","LU0965509010.AUD","LU1670627923.USD","BK4539","LU0310799852.SGD","LU0158827948.USD","LU0203345920.USD"],"gpt_icon":1},{"id":"2505858089","title":"Psyence Biomedical files to sell 3.075M common shares for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2505858089","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505858089?lang=en_us&edition=fundamental","pubTime":"2025-01-24 19:10","pubTimestamp":1737717031,"startTime":"0","endTime":"0","summary":"06:09 EST Psyence Biomedical (PBM) files to sell 3.075M common shares for holders Published first on TheFly – the ultimate source for real-time, ma...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/psyence-biomedical-files-to-sell-3-075m-common-shares-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/psyence-biomedical-files-to-sell-3-075m-common-shares-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2503622904","title":"FTC Report Reveals PBM Practices Impacting Competition and Drug Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2503622904","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503622904?lang=en_us&edition=fundamental","pubTime":"2025-01-15 23:28","pubTimestamp":1736954880,"startTime":"0","endTime":"0","summary":"The FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty generic drugs, resulting in $7.3 billion in excess revenue.The report highlighted that the national average acquisition costs for medications used to treat critical conditions like cancer, HIV, and heart disease were often exceeded by markups of over $1,000.While the companies concerned are still reviewing the report, CVS and CI mentioned that FTC is focusing on specialty generic products, which account for 1-2% of total client drug spend, resulting in misleading outcomes. UNH’s Optum asserted that its role is to negotiate and reduce the prices of drugs for plan sponsors and customers and that it saved $1.3 billion in 2024 alone. UNH carries a Zacks Rank #3 , reflecting a neutral outlook, while CI and CVS carry a Zacks Rank #4  and Zacks Rank #5 , respectively,indicating more bearish sentimen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ftc-report-reveals-pbm-practices-152800151.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1674673691.USD","LU0079474960.USD","LU0661504455.SGD","IE00B19Z8W00.USD","LU0211328371.USD","SGXZ31699556.SGD","BK4588","LU0976567544.SGD","SG9999014880.SGD","PBM","SG9999001176.USD","LU2028103732.USD","CI","LU2242649171.HKD","LU2468319806.SGD","LU2112291526.USD","LU0211326755.USD","LU0058720904.USD","LU1988902786.USD","LU1066051498.USD","IE0009355771.USD","LU0094547139.USD","IE00B19Z9Z06.USD","FTC","LU0787776722.HKD","IE0002270589.USD","LU2461242641.AUD","LU0949170772.SGD","LU1506573853.SGD","LU0128525929.USD","LU0158827781.USD","LU0211327993.USD","LU0965509101.SGD","SG9999013999.USD","LU0795875086.SGD","CVS","LU0868494617.USD","LU1732799900.SGD","LU0545039389.USD","BK4504","IE00BFSS7M15.SGD","LU1791710582.SGD","LU0158827948.USD","UNH","IE0004445015.USD","BK4196","LU2491049909.HKD","LU1003077747.HKD","IE00BZ1G4Q59.USD","LU1037948541.HKD"],"gpt_icon":1},{"id":"2503645752","title":"CVS Health: Current Price Offers Favorable Risk-Reward Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2503645752","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503645752?lang=en_us&edition=fundamental","pubTime":"2025-01-15 21:01","pubTimestamp":1736946098,"startTime":"0","endTime":"0","summary":"CVS Health Corporation  is a vertically integrated healthcare corporation in the United States. The company owns a leading healthcare benefits provider, a leading pharmacy benefits manager , and one of the largest retail pharmacy chains in the country. As an integrated healthcare service provider, CVS plays a significant role in the U.S. healthcare system. Recently, CVS has faced a number of challenges, which led to the appointment of a new CEO and four new Board members. Amid these challenges, CVS's stock price declined by more than 40 percent in 2024. After a prolonged decline, the stock is trading at less than 10 times trailing-twelve-month earnings and less than 9 times estimated 2025 earnings. Meanwhile, the company continues to generate substantial cash flow. I believe CVS represents a great value opportunity at its current price.GuruFocus has detected 4 Warning Signs with CVS.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cvs-health-current-price-offers-130138388.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1059921491.USD","LU0061475181.USD","IE00BZ1G4Q59.USD","BK4585","LU0208291251.USD","MLR","LU1699723380.USD","PBM","BK4196","BK4550","BK4149","LU0211331839.USD","BK4581","LU0006061336.USD","IE00BKVL7J92.USD","LU0072461881.USD","FTC","BK4588","BK4504","CVS","LU0162691827.USD","BK4139","IE00BSNM7G36.USD","LU0070302665.USD","LU1571399168.USD","LU0320765489.SGD"],"gpt_icon":0},{"id":"2503509817","title":"FTC releases second report on PBM price hikes of specialty drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2503509817","media":"Yahoo Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503509817?lang=en_us&edition=fundamental","pubTime":"2025-01-15 00:59","pubTimestamp":1736873995,"startTime":"0","endTime":"0","summary":"The Federal Trade Commission  released a 60-page report Tuesday targeting the three biggest pharmacy benefit managers , claiming the companies hiked the prices of specialty drugs by thousands of percent to generate $7.3 billion in revenue, collectively, from 2017 to 2022.This is the FTC's second interim report on the industry, which it has accused of excessive profits and contributing to higher overall healthcare costs through significant market control in the US.“The FTC staff’s second interim report finds that the three major pharmacy benefit managers hiked costs for a wide range of lifesaving drugs, including medications to treat heart disease and cancer,” said FTC Chair Lina Khan in a statement Tuesday.Khan added that the FTC should continue investigating the PBMs and \"should act swiftly to stop any illegal conduct.\". UNITED STATES - JULY 13: FTC Chairwoman Lina Khan prepares to testify during the House Judiciary Committee hearing titled \"Oversight of the Federal Trade Commission,\"","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ftc-releases-second-report-on-pbm-price-hikes-of-specialty-drugs-165955414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0011850046.USD","LU1037948541.HKD","LU1699723380.USD","IE00B7KXQ091.USD","LU1854103824.USD","LU2089284900.SGD","IE00B19Z3581.USD","LU0316494557.USD","LU2357305700.SGD","PBM","UNH","LU2133065610.SGD","IE00B19Z9505.USD","LU1066053197.SGD","LU1506573853.SGD","IE00B19Z3B42.SGD","LU1791710400.SGD","LU0310800379.SGD","BK4581","LU0672654240.SGD","LU0251132253.USD","LU2028103732.USD","SGXZ99366536.SGD","LU1035773651.USD","LU2125154778.USD","LU2361044949.HKD","FTC","LU0006061336.USD","LU2361045086.USD","LU1571399168.USD","IE00BJJMRY28.SGD","LU0708994859.HKD","LU1778281490.HKD","CI","IE0004445239.USD","LU0965509101.SGD","LU1551013342.USD","IE0002141913.USD","IE000M9KFDE8.USD","LU0320765489.SGD","LU1066051225.USD","IE0004445015.USD","CVS","LU0820561909.HKD","LU0234572021.USD","LU0208291251.USD","LU2264538146.SGD","BK4588","LU0965509283.SGD","LU0070302665.USD"],"gpt_icon":1},{"id":"2503932303","title":"Can Walgreens Boots Alliance Stock Keep Soaring?","url":"https://stock-news.laohu8.com/highlight/detail?id=2503932303","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503932303?lang=en_us&edition=fundamental","pubTime":"2025-01-13 00:23","pubTimestamp":1736698980,"startTime":"0","endTime":"0","summary":"A better-than-expected fiscal first-quarter report recently lifted Walgreens Boots Alliance stock 27.5% in a single trading session.Shares of Walgreens offer a huge 8.5% dividend yield at recent prices.Profit margins for Walgreens' U.S. pharmacy operation are shrinking.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/01/12/can-walgreens-boots-alliance-stock-keep-soaring/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU0321505868.SGD","BK4588","BK4139","WBA","PBM","BK4128","LU0321505439.SGD","BK4585"],"gpt_icon":0},{"id":"2501347787","title":"Headline Risks Affecting Healthcare Tech & Distribution Sector Will Likely Continue in 2025: BofA Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2501347787","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501347787?lang=en_us&edition=fundamental","pubTime":"2025-01-08 01:03","pubTimestamp":1736269424,"startTime":"0","endTime":"0","summary":"BofA Securities predicts that headline risks affecting the Healthcare Tech & Distribution sector in 2024 will likely continue in 2025.Key areas of concern include pharmacy benefit managers , retail pharmacies, distributors, fertility benefits, and direct-to-consumer  pharmacies.While regulatory pressure on PBMs is expected to persist, the analyst believes this will mainly impact profit margins and growth rates rather than lead to major changes in the business model.Potential policy shifts under the next administration could involve adjustments to the Inflation Reduction Act, expanded access to health savings accounts , and increased support for fertility benefits.BofA upgraded Cardinal Health Inc.  from Neutral to Buy. The analyst notes Cardinal Health’s core pharmaceutical segment is growing faster than its competitors, with this trend expected to strengthen in the coming year.The company is benefiting from a unique advantage in its pharmacy benefit management  business, which could a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/headline-risks-affecting-healthcare-tech-170344350.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1037948897.HKD","LU0122379950.USD","BK4585","LU2112291526.USD","LU0912757837.SGD","LU1548497426.USD","LU1989772923.USD","HCSG","LU1267930813.SGD","LU0310800965.SGD","LU0742534661.SGD","LU0868494617.USD","PBM","LU0965509010.AUD","LU1267930227.SGD","LU1571399168.USD","LU0048573561.USD","LU0320765646.SGD","LU1023059063.AUD","LU0006306889.USD","LU2324357040.USD","SG9999001440.SGD","LU0795875169.SGD","LU2468319806.SGD","LU0006061336.USD","HSIC","LU0942090050.USD","LU0861579265.USD","LU2357305700.SGD","LU1880398471.USD","LU1934455194.USD","LU0225283273.USD","LU0072461881.USD","BK4175","LU1880398554.USD","MCK","LU2089283258.USD","LU2347655156.SGD","LU0106831901.USD","LU0310799852.SGD","LU0314104364.USD","LU1061106388.HKD","LU0971096721.USD","LU1037948541.HKD","LU2089984988.USD","LU1430594728.SGD","LU2028103732.USD","BK4137","LU0889566641.SGD","CAH"],"gpt_icon":0},{"id":"2495270541","title":"Psyence Biomedical Closes $2 Million Private Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2495270541","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495270541?lang=en_us&edition=fundamental","pubTime":"2024-12-30 21:03","pubTimestamp":1735563807,"startTime":"0","endTime":"0","summary":"Psyence Biomedical  said late Friday it has completed its private placement for gross proceeds of $2 million.The company offered 1 million common shares or pre-funded warrants, series A warrants to purchase up to 1 million shares, and short-term series B warrants to purchase up to 1 million shares at a purchase price of $2 per share or per pre-funded warrant and accompanying series A and B warrants.The warrants have an exercise price of $2 per share and are exercisable immediately upon issuance.Proceeds from the offering are expected to be used for general corporate purposes, the company said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PBM","BK4139"],"gpt_icon":0},{"id":"2495514878","title":"Drug Middlemen Got Spared By Trump and Musk -- Heard on the Street -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2495514878","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495514878?lang=en_us&edition=fundamental","pubTime":"2024-12-30 18:30","pubTimestamp":1735554600,"startTime":"0","endTime":"0","summary":"Tucked into the bipartisan budget deal that President-elect Donald Trump's allies torpedoed earlier this month was a rare and significant attempt to reform the mechanics of America's drug-pricing system.Americans are broadly aware of how big pharma profits from high drug prices, but few understand the market distortions introduced by pharmacy benefit management  companies that negotiate prices on behalf of employers, insurers and government programs.The failed budget bill included provisions that would have addressed some of the misaligned incentives within the PBM business model. But health conglomerates Cigna, CVS Health and UnitedHealth Group, which own the three largest PBMs, caught a break when Elon Musk, Vivek Ramaswamy and other Trump allies began agitating against the bill. This set off a frantic effort in Washington to pass a stripped-down version of the legislation that no longer contained many extraneous measures, including the PBM changes.PBMs, once obscure entities in the ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0256863811.USD","LU0251132253.USD","LU2491050071.SGD","LU1057294990.SGD","LU0266013472.USD","LU0868494617.USD","LU2362541273.HKD","LU0417517546.SGD","LU2279689827.SGD","LU0053666078.USD","LU0234572021.USD","LU1267930490.SGD","LU0029864427.USD","LU1571399168.USD","SG9999001176.SGD","LU1720051017.SGD","PBM","IE00B2B36J28.USD","SGXZ31699556.SGD","IE0004445015.USD","CI","LU2324357040.USD","IE00B7KXQ091.USD","LU1003077747.HKD","LU0965509010.AUD","LU0208291251.USD","LU2491050154.USD","LU1988902786.USD","LU1023059063.AUD","LU2125154935.USD","LU2087625088.SGD","IE00B7SZLL34.SGD","LU0061475181.USD","LU0079474960.USD","LU0738911758.USD","LU2244417387.USD","LU1778281490.HKD","LU1061106388.HKD","LU0965508806.USD","LU0795875086.SGD","LU1854103824.USD","LU2125154778.USD","LU0211327993.USD","UNH","LU1261432733.SGD","CVS","LU0320765059.SGD","LU2112291526.USD","LU0070302665.USD"],"gpt_icon":1},{"id":"2495512795","title":"Is UnitedHealth Group Stock a Buy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2495512795","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495512795?lang=en_us&edition=fundamental","pubTime":"2024-12-30 17:53","pubTimestamp":1735552380,"startTime":"0","endTime":"0","summary":"Shares of what may be America's most powerful healthcare company have declined due to controversy and regulatory threats.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2024/12/30/is-unitedhealth-group-stock-a-buy/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU0787776722.HKD","IE00B894F039.SGD","LU2362540622.SGD","LU0077335932.USD","LU2111349929.HKD","IE00BFTCPJ56.SGD","PBM","LU0976567544.SGD","LU1934455277.USD","LU2362541513.USD","LU1496350502.SGD","LU1084165304.USD","LU1548497426.USD","LU1791710582.SGD","LU2089283258.USD","LU2461242641.AUD","LU1778281490.HKD","TTM","LU0256863811.USD","LU0345770993.USD","LU1732800096.USD","LU1814569148.SGD","LU2361044865.SGD","UNH","IE00B1BXHZ80.USD","LU2324357040.USD","LU0211326839.USD","LU1670628061.USD","LU2236285917.USD","LU0203345920.USD","IE00B4JS1V06.HKD","IE00BJJMRY28.SGD","LU1267930730.SGD","SG9999002232.USD","SG9999017495.SGD","LU2491050154.USD","LU0107464264.USD","LU0122379950.USD","BK4154","LU0545039389.USD","LU1074936037.SGD","LU0353189680.USD","LU1323610961.USD","SG9999001176.USD","LU1989771016.USD","LU1791710400.SGD","LU2089284900.SGD"],"gpt_icon":1},{"id":"2495265023","title":"CVS Health Corporation (CVS): Among the Cheap Healthcare Stocks to Buy Heading Into 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2495265023","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495265023?lang=en_us&edition=fundamental","pubTime":"2024-12-29 05:54","pubTimestamp":1735422886,"startTime":"0","endTime":"0","summary":"We recently compiled a list of the 12 Cheap Healthcare Stocks to Buy Heading into 2025.In this article, we are going to take a look at where CVS Health Corporation  stands against the other cheap healthcare stocks.The Resilience and Challenges of Global Healthcare Spending. Investing in healthcare equities is typically seen as protective during recessionary times. This is because, even in hard financial times, consumers usually do not reduce their usage of prescription drugs or other necessary healthcare services. National healthcare spending is expected to reach an estimated $4.8 trillion in 2023 and increase at a 5.6% annual pace between 2027 and 2032, according to the Centers for Medicare and Medicaid Services .Nevertheless, the U.S. spends over twice as much on healthcare as the OECD average, despite these difficulties, and the average results are poorer. This discrepancy emphasizes how ineffective and unsustainable the c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cvs-health-corporation-cvs-among-215446414.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1145028129.USD","LU0056508442.USD","LU1989772923.USD","LU2764263203.CNY","LU0823421416.USD","LU0957791311.USD","LU0162691827.USD","LU2346227817.USD","LU0889565833.HKD","LU1718418525.SGD","PBM","LU0820561818.USD","LU0006061336.USD","LU0198837287.USD","LU0345769128.USD","LU0061475181.USD","LU0061474705.USD","LU0127658192.USD","BK4585","LU0072461881.USD","LU0823434740.USD","LU0320765059.SGD","LU0006306889.USD","LU0353189680.USD","LU1699723380.USD","CVS","LU1316542783.SGD","LU0708995401.HKD","LU0061474960.USD","IE00B4JS1V06.HKD","IE00BJJMRY28.SGD","LU2361044865.SGD","LU0868494617.USD","IE00BWXC8680.SGD","HCSG","IE00BYQQ9H92.USD","LU0256863811.USD","LU2213496289.HKD","LU2317271919.USD","SGXZ81514606.USD","LU0823434583.USD","LU1989764748.USD","LU2764263039.SGD","LU2361044949.HKD","CMS","LU1363072403.SGD","LU0820561909.HKD","LU0289941410.SGD","MA","LU2637428348.USD"],"gpt_icon":0},{"id":"2494358828","title":"Psyence Biomed Announces Closing of $2.0 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2494358828","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494358828?lang=en_us&edition=fundamental","pubTime":"2024-12-28 05:05","pubTimestamp":1735333535,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241227:nTUA1FVJQG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2494358817","title":"Press Release: Psyence Biomed Announces Closing of $2.0 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2494358817","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494358817?lang=en_us&edition=fundamental","pubTime":"2024-12-28 05:05","pubTimestamp":1735333500,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec. 27, 2024  -- Psyence Biomedical Ltd.   today announced that it has closed its previously announced private placement for the purchase and sale of an aggregate of 1,000,000 common shares , series A common warrants to purchase up to 1,000,000 common shares and short-term series B common warrants to purchase up to 1,000,000 common shares at a purchase price of $2.00 per common share  and accompanying series A common warrant and short-term series B common warrant. The series A common warrants and short-term series B common warrants have an exercise price of $2.00 per share and are exercisable immediately upon issuance. The series A common warrants expire five years from the date of issuance and the short-term series B common warrants expire two years from the date of issuance.Psyence Biomedical Ltd.  is the world's first life science biotechnology company developing nature-derived  psilocybin-based psychedelic medicines to be listed on Nasdaq. Psyence is initially working to","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PBM","NQmain"],"gpt_icon":0},{"id":"2493767468","title":"Psyence Biomedical Regains Nasdaq Compliance for Continued Listing","url":"https://stock-news.laohu8.com/highlight/detail?id=2493767468","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493767468?lang=en_us&edition=fundamental","pubTime":"2024-12-24 00:17","pubTimestamp":1734970634,"startTime":"0","endTime":"0","summary":"Psyence Biomedical  said Monday it received a Nasdaq notification that the firm has regained compliance with all applicable Nasdaq listing requirements, including minimum market value and stockholders' equity requirement.\"With Nasdaq compliance, a debt free balance sheet and a cash position of $5.6 million, the company is well positioned to execute its business plan and clinical trial, for which patient screening has commenced,\" Psyence said.Price: 2.37, Change: -0.81, Percent Change: -25.47","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["USJW.SI",".IXIC","PBM","NVIW.SI","NDAQ","BK4588","BK4112","LU2210150020.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","QID","BK4139","TSYW.SI","LU2095319765.USD","PSQ","IE00BGHQF748.EUR","BK4585","IE00B3QW5Z07.USD","QLD","TQQQ","IE00BKPKM429.USD","USAW.SI","MNQmain","NQmain","SQQQ"],"gpt_icon":1},{"id":"2493750166","title":"Psyence Biomedical Expects to Raise $2 Million From Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2493750166","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493750166?lang=en_us&edition=fundamental","pubTime":"2024-12-23 21:40","pubTimestamp":1734961235,"startTime":"0","endTime":"0","summary":"Psyence Biomedical  said Monday it has agreed to a private placement of 1 million common shares or pre-funded warrants, along with accompanying series A and series B warrants, priced at $2 each for expected gross proceeds of $2 million.The company said the series A warrants expire in five years, while the series B warrants expire in two years. Both warrants, exercisable immediately after issuance, will have an exercise price of $2. it added.Net proceeds from the offering, slated to close around Tuesday, will be used for working capital and general purposes, Psyence said.Shares of the company were down more than 15% in recent Monday premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PBM"],"gpt_icon":0},{"id":"2493757921","title":"Psyence Biomedical prices 1M shares at $2.00 in private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2493757921","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493757921?lang=en_us&edition=fundamental","pubTime":"2024-12-23 21:15","pubTimestamp":1734959732,"startTime":"0","endTime":"0","summary":"Psyence Biomedical (PBM) has entered into definitive agreements for the purchase and sale of an aggregate of 1,000,000 common shares series A commo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/psyence-biomedical-prices-1m-shares-at-2-00-in-private-placement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/psyence-biomedical-prices-1m-shares-at-2-00-in-private-placement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PBM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.pacificbooker.bc.ca","stockEarnings":[{"period":"1week","weight":0.022},{"period":"1month","weight":-0.1494},{"period":"3month","weight":-0.6324},{"period":"6month","weight":-0.9654},{"period":"1year","weight":-0.972},{"period":"ytd","weight":-0.3389}],"compareEarnings":[{"period":"1week","weight":0.0149},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0409},{"period":"6month","weight":0.0999},{"period":"1year","weight":0.2145},{"period":"ytd","weight":0.0403}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.259967},{"month":2,"riseRate":0.5,"avgChangeRate":-0.199641},{"month":3,"riseRate":1,"avgChangeRate":0.362272},{"month":4,"riseRate":0.666667,"avgChangeRate":-0.067007},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.053855},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.193429},{"month":7,"riseRate":1,"avgChangeRate":0.326596},{"month":8,"riseRate":0.666667,"avgChangeRate":-0.094421},{"month":9,"riseRate":0.666667,"avgChangeRate":-0.251038},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.101551},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.109939},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.187578}],"exchange":"NASDAQ","name":"Psyence Biomedical Ltd","nameEN":"Psyence Biomedical Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Psyence Biomedical Ltd(PBM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Psyence Biomedical Ltd(PBM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Psyence Biomedical Ltd,PBM,Psyence Biomedical Ltd股票,Psyence Biomedical Ltd股票老虎,Psyence Biomedical Ltd股票老虎国际,Psyence Biomedical Ltd行情,Psyence Biomedical Ltd股票行情,Psyence Biomedical Ltd股价,Psyence Biomedical Ltd股市,Psyence Biomedical Ltd股票价格,Psyence Biomedical Ltd股票交易,Psyence Biomedical Ltd股票购买,Psyence Biomedical Ltd股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Psyence Biomedical Ltd(PBM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Psyence Biomedical Ltd(PBM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction